Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DB26FX1LG
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,683
Award facts
- Contract value 100% obligated
- $5,682.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $5,682.96 to DMS Pharmaceutical Group Inc. for the supply of Nexplanon 68 mg implants, with an ultimate completion date of December 2, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that positions the company as a critical regional pharmaceutical supplier for Department of Defense healthcare operations.
The Nexplanon implant delivery supports the contraceptive product line within DMS Pharmaceutical Group's comprehensive pharmaceutical portfolio, which includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The underlying IDC, designated as contract SPE2DR and valued at a $499,999,999 ceiling, was awarded on November 13, 2025, with a completion date of December 31, 2036, featuring a 30-month base period and three 30-month option periods. This contract structure enables the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring medical supply needs of military healthcare facilities worldwide, with DMS Pharmaceutical Group's established performance history demonstrating its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FX1LG?
SPE2DB26FX1LG was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 7, 2025.
How much is contract SPE2DB26FX1LG worth?
The government has obligated $5,683 on SPE2DB26FX1LG.
Is contract SPE2DB26FX1LG an order under another contract?
Yes. SPE2DB26FX1LG is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1LG competed?
The extent of competition for SPE2DB26FX1LG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award